LONDON (Alliance News) - Specialist medical technology company Angle PLC on Tuesday said it has recruited the first patient for its European ovarian cancer study.
Three cancer centres in Berlin and one in Vienna are now also actively recruiting patients.
The study will examine 200 women diagnosed with a pelvic mass, analysing blood using Angle's Parsortix system and RNA from the cell harvests to detect the presence or absence of ovarian circulating tumour cells. The aim is to discriminate successfully between women with benign and malignant masses.
The first half of patients enrolled into the study will be used as a "training set" to determine which of the RNA markers previously investigated are optimal for the detection of ovarian cancer CTCs harvested by the Parsortix system.
The remainder of the patients enrolled into the study will be used as a "verification set" to verify that those RNA markers are successful at discriminating between women with benign and malignant pelvic masses for pre-surgical triaging.
Angle aims to complete the study by the end of 2016. Successful completion will allow it to offer the Parsortix system to European hospitals, and it is also working on plans to execute a similar study in the US.
"It has been a huge effort to put this clinical study in place and we are now excited to see the study in progress. The four participating centres are enthusiastic and committed and we look forward to the next stage of development of this important clinical application," Founder & Chief Executive Andrew Newland said in a statement.
Shares in Angle were trading up 4% at 68.65 pence on Tuesday morning.
By Karolina Kaminska; karolinakaminska@alliancenews.com @KarolinaAllNews
Copyright 2016 Alliance News Limited. All Rights Reserved.
Angle (AGL)